Publication & Citation Trends
Publications
0 total
A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants
Cited by 0
Semantic Scholar
Clinical Formulation Bridging of Gefapixant, a P2X3‐Receptor Antagonist, for the Treatment of Chronic Cough OA
Cited by 7
Semantic Scholar
A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults
Cited by 1
Semantic Scholar
Experimental Medicine Study to Measure Immune Checkpoint Receptors PD‐1 and GITR Turnover Rates In Vivo in Humans OA
Cited by 5
Semantic Scholar
Evaluation of Therapeutics for Severely Debilitating or Life‐Threatening Diseases or Conditions: Defining Scope to Enable Global Guidance Development
Cited by 7
Semantic Scholar
Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with 18F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles OA
Cited by 99
Semantic Scholar
546. No Difference in MK-8591 and Doravirine Pharmacokinetics After Co-Administration OA
Cited by 3
Semantic Scholar
Research Topics
HIV/AIDS drug development and treatment
(7)
Diabetes Treatment and Management
(4)
Drug Transport and Resistance Mechanisms
(4)
Pharmacological Effects and Toxicity Studies
(4)
Bone health and osteoporosis research
(3)
Affiliations
Merck & Co., Inc., Rahway, NJ, USA (United States)
University of California, Los Angeles
Gwynedd Mercy University